NCT01424033终止2 期
Clinical Trial of Oral Medication for CTD-ILD Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Pulmonary Function Tests
研究概览
简要总结
The first objective of this protocol is to assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).
详细描述
The investigators will assess tolerability and safety at scheduled intervals via standard of care physical exam findings, monitoring complete blood count, serum chemistry, and pulmonary function tests, along with patient reports of medication intolerance and change in symptoms of dyspnea.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
N-Acetylcysteine
Experimental
This is an open label trial, all patient will be entered into one treatment arm.
干预措施: N-Acetylcysteine (Drug)
结局指标
主要结局
Pulmonary Function Tests
时间窗: Every 3 months
Not recorded. Study terminated due to departure of PI.
次要结局
未报告次要终点
研究者
Kristine Phillips
M.D.
University of Michigan
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study Evulating DA-302168S Tablets in Overweight/Obese SubjectsOverweight and ObesityNCT06541730Chendu DIAO Pharmaceutical Group CO., LTD.48
招募中
1 期
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)Chronic Myeloid Leukemia, Chronic PhaseChronic Myeloid LeukemiaNCT06163430Terns, Inc.180
招募中
1 期
A Phase I Study of CFT8919 in Patients With Advanced NSCLCNon-Small Cell Lung Cancer With EGFR MutationNCT06641609Betta Pharmaceuticals Co., Ltd.166
已完成
1 期
Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy SubjectsChronic HBV InfectionNCT05468060Zhejiang Palo Alto Pharmaceuticals, Inc.80
已完成
1 期
Phase I Study on VEGF Vaccination in Metastatic Solid TumorsMetastatic CancerNCT02237638Amsterdam UMC, location VUmc30